2023
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventionsWeight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder
Carr M, Wolkowicz N, Cave S, Martino S, Masheb R, Midboe A. Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder. Journal Of Psychiatric Research 2023, 168: 204-212. PMID: 37918033, DOI: 10.1016/j.jpsychires.2023.10.012.Peer-Reviewed Original ResearchConceptsOpioid use disorderMethadone treatmentBuprenorphine treatmentUse disordersMedication treatmentWeight changeVeterans Health Administration (VHA) administrative dataWeight gainSignificant weight gainCourse of treatmentU.S. military veteransTreatment episodesNational cohortObservation periodMilitary veteransLinear mixed modelsVeteransTreatmentBMIDisordersAdministrative dataCohortFiscal year 2017Fiscal year 2019Mixed modelsEconomic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross J, Marsh E, Weitz M, Savinkina A, Schackman B, Wang J, Madushani R, Morgan J, Barocas J, Walley A, Chrysanthopoulou S, Linas B, Assoumou S. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Network Open 2023, 6: e2329583. PMID: 37703018, PMCID: PMC10500382, DOI: 10.1001/jamanetworkopen.2023.29583.Peer-Reviewed Original ResearchConceptsExtended-release buprenorphineIncremental cost-effectiveness ratioMedication treatmentHealth care utilization costsTreatment of OUDOpioid agonist treatmentOpioid use disorderMean lifetime costsCost-effectiveness ratioProbabilistic sensitivity analysesEconomic evaluationCohort studyAgonist treatmentTreatment optionsClinical trialsClosed cohortMAIN OUTCOMEBuprenorphineSimulated cohortUse disordersDrug AdministrationUS FoodPharmaceutical costsQALY willingnessInjectable formWeight change among patients engaged in medication treatment for opioid use disorder: a scoping review
Carr M, Lou R, Macdonald-Gagnon G, Peltier M, Funaro M, Martino S, Masheb R. Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review. The American Journal Of Drug And Alcohol Abuse 2023, 49: 551-565. PMID: 37200510, PMCID: PMC10840392, DOI: 10.1080/00952990.2023.2207720.Peer-Reviewed Original ResearchConceptsOpioid use disorderExcess weight gainWeight gainMedication treatmentUse disordersType of MOUDBuprenorphine/naloxoneRetrospective chart reviewUse of methadoneBody mass indexModerate weight gainMOUD initiationChart reviewCohort studyOpioid useBuprenorphine/Mass indexMedication doseMethadone treatmentNonrandomized studyCase reportEthnic disparitiesPotential associationMOUDPatientsBuprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration
Gordon A, Saxon A, Kertesz S, Wyse J, Manhapra A, Lin L, Chen W, Hansen J, Pinnell D, Huynh T, Baylis J, Cunningham F, Ghitza U, Bart G, Yu H, Sauer B. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug And Alcohol Dependence 2023, 248: 109902. PMID: 37196572, PMCID: PMC10875624, DOI: 10.1016/j.drugalcdep.2023.109902.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Health AdministrationUse disordersHealth AdministrationOpioid use disorder treatmentHalf of patientsOpen cohort studyRetention of patientsCourse of careUse disorder treatmentLarge healthcare systemCohort studyMedian durationPatient characteristicsPatient demographicsDaily doseMedication treatmentBuprenorphine useClinical dataWhite racePatientsProportion daysDisorder treatmentMultiple coursesHealthcare systemPerspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs
Sue K, Chawarski M, Curry L, McNeil R, Coupet E, Schwartz R, Wilder C, Tsui J, Hawk K, D’Onofrio G, O’Connor P, Fiellin D, Edelman E. Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs. JAMA Network Open 2023, 6: e2312718. PMID: 37163263, PMCID: PMC10173026, DOI: 10.1001/jamanetworkopen.2023.12718.Peer-Reviewed Original ResearchConceptsCommunity-based cliniciansOpioid use disorderEmergency departmentOUD treatmentMedication treatmentSubstance use disorders trainingUrban academic emergency departmentEffectiveness-implementation studyAcademic emergency departmentDisorder treatment settingsPerspectives of cliniciansCommunity-based treatmentCommunity-based treatment programsStaff perspectivesImplementation science frameworkBuprenorphine programTreatment cliniciansPeer navigatorsReferral sitesPromoting ActionMAIN OUTCOMEED staffBuprenorphineFocus groupsUse disordersRacial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems
Holland W, Li F, Nath B, Jeffery M, Stevens M, Melnick E, Dziura J, Khidir H, Skains R, D'Onofrio G, Soares W. Racial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems. Academic Emergency Medicine 2023, 30: 709-720. PMID: 36660800, PMCID: PMC10467357, DOI: 10.1111/acem.14668.Peer-Reviewed Original ResearchConceptsOpioid use disorderCommunity emergency departmentsEmergency departmentDischarge diagnosisHealth care systemHispanic patientsBlack patientsHospital typeCare systemNon-Hispanic patientsOpioid overdose deathsClinical decision support systemOpioid withdrawalPrimary outcomeMedication treatmentBuprenorphine accessED treatmentTreatment accessOverdose deathsX-waiverBuprenorphinePatientsUse disordersEthnic disparitiesSecondary analysis
2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatusWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal Of Biological Psychiatry 2022, 24: 118-134. PMID: 35900217, DOI: 10.1080/15622975.2022.2086296.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsRepetitive transcranial magnetic stimulationCognitive behavioral therapyFirst-line treatmentDeep brain stimulationSSRI treatmentBiological Psychiatry (WFSBP) GuidelinesSecond-line medicationsNon-pharmacological treatmentSerotonin reuptake inhibitorsNon-pharmacological interventionsTreatment-resistant casesTranscranial magnetic stimulationWorld FederationTreatment of anxietyPosttraumatic stress disorderTreatment of OCDReuptake inhibitorsMedication treatmentPharmacological treatmentSNRI venlafaxineInternet-CBTConsensus panelMagnetic stimulationBrain stimulationModels for Implementing Emergency Department–Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers
Whiteside LK, D'Onofrio G, Fiellin DA, Edelman EJ, Richardson L, O'Connor P, Rothman RE, Cowan E, Lyons MS, Fockele CE, Saheed M, Freiermuth C, Punches BE, Guo C, Martel S, Owens PH, Coupet E, Hawk KF. Models for Implementing Emergency Department–Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers. Annals Of Emergency Medicine 2022, 80: 410-419. PMID: 35752520, PMCID: PMC9588652, DOI: 10.1016/j.annemergmed.2022.05.010.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersEmergency department-initiated buprenorphineEmergency department dischargeEmergency department patientsElectronic medical record integrationAcademic medical centerBuprenorphine programDepartment patientsTreatment initiationMedication treatmentEmergency physiciansMedical CenterAmerican CollegeClinical practiceImplementation facilitationQuality improvement processBuprenorphineCommon facilitatorsRecord integrationPatientsReferralED cultureEducational disseminationDisordersGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersRationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATIONCocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse And Rehabilitation 2022, 13: 25-46. PMID: 36093428, PMCID: PMC9451050, DOI: 10.2147/sar.s337338.Peer-Reviewed Original ResearchCocaine use disorderCo-occurring disordersUse disordersCommon co-occurring disordersCurrent clinical perspectivesSubstance use disordersCognitive behavioral therapyMedication treatmentPharmacological treatmentRisk factorsCurrent treatmentDevastating disorderLarger sample sizeTreatment planChronic effectsCocaine useBehavioral treatmentClinical perspectiveBehavioral interventionsDisordersTreatmentFuture studiesMost individualsIndividualsSample size
2021
Antiseizure Medication Treatment and Outcomes in Patients with Subarachnoid Hemorrhage Undergoing Continuous EEG Monitoring
Zafar SF, Rosenthal ES, Postma EN, Sanches P, Ayub MA, Rajan S, Kim JA, Rubin DB, Lee H, Patel AB, Hsu J, Patorno E, Westover MB. Antiseizure Medication Treatment and Outcomes in Patients with Subarachnoid Hemorrhage Undergoing Continuous EEG Monitoring. Neurocritical Care 2021, 36: 857-867. PMID: 34843082, PMCID: PMC9117405, DOI: 10.1007/s12028-021-01387-x.Peer-Reviewed Original ResearchConceptsAneurysmal subarachnoid hemorrhageGood functional outcomeAntiseizure medicationsFunctional outcomeContinuous electroencephalographyEpileptiform activityLower likelihoodBetter outcomesAneurysm treatmentRetrospective single-center cohort studySingle-center cohort studyAntiseizure medication (ASM) treatmentElectroencephalographic epileptiform activityResultsNinety-four patientsDay of admissionContinuous EEG monitoringASM treatmentCEEG initiationCohort studyProspective trialHigh-intensity treatmentLow-intensity treatmentMedication treatmentSubarachnoid hemorrhageOutcome measuresDesign and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphineGender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Abuse 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVCOVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bermas B, Gianfrancesco M, Tanner H, Seet A, Aguiar M, Al Adhoubi N, Al Emadi S, Cunha B, Flood R, Kusevich D, McCarthy E, Patel N, Ruderman E, Sattui S, Sciascia S, Siddique F, Valenzuela-Almada M, Wise L, Worthing A, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann J, Hyrich K, Lawson-Tovey S, Liew J, Sirotich E, Sparks J, Sufka P, Wallace Z, Machado P, Strangfeld A, Clowse M, Yazdany J, Robinson P. COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance. The Journal Of Rheumatology 2021, 49: 110-114. PMID: 34470798, DOI: 10.3899/jrheum.210480.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPregnant womenPregnancy outcomesObstetric detailsCOVID-19Combination of antimalarialsRheumatic disease diagnosisLopinavir/ritonavirSystemic lupus erythematosusCases of patientsCOVID-19 infectionCoronavirus disease 2019Time of infectionCOVID-19 diagnosisTime of reportAntiphospholipid syndromeInflammatory arthritidesPreterm birthLupus erythematosusMedian ageTerm birthsRheumatoid arthritisSupplemental oxygenArthritis/Medication treatmentA Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open Forum Infectious Diseases 2021, 8: ofab289. PMID: 34430670, PMCID: PMC8378589, DOI: 10.1093/ofid/ofab289.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusInfectious disease outcomesViral suppressionUse disordersVirologic responseDisease outcomeHuman immunodeficiency virus (HIV) viral suppressionNew hepatitis B virus (HBV) infectionsHepatitis B virus infectionGreater ART adherenceTreatment of OUDB virus infectionHIV viral suppressionAntiretroviral therapy adherenceImpact of medicationHCV reinfectionART adherenceMedication treatmentTherapy adherenceHIV treatmentInfectious disease epidemicsC virusOpioid epidemicTreatment outcomesImpact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV
Kennedy AJ, McGinnis KA, Merlin JS, Edelman EJ, Gordon AJ, Korthuis PT, Skanderson M, Williams EC, Wyse J, Oldfield B, Bryant K, Justice A, Fiellin DA, Kraemer KL. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. Journal Of Substance Use And Addiction Treatment 2021, 132: 108509. PMID: 34130128, PMCID: PMC8628025, DOI: 10.1016/j.jsat.2021.108509.Peer-Reviewed Original ResearchConceptsOpioid use disorderVACS Index 2.0Viral loadMOUD receiptART initiationCD4 countART adherenceUse disordersVeterans Aging Cohort Study (VACS) dataBehavioral treatmentHIV clinical outcomesLog viral loadCD4 cell countAntiretroviral treatment initiationCohort study dataPoor health outcomesPre-post changesHIV outcomesTreatment initiationClinical outcomesMedication treatmentMOUD treatmentPWHHealth outcomesCell countCommentary: Diagnostic Challenges in Evaluating Adolescents
Garakani A. Commentary: Diagnostic Challenges in Evaluating Adolescents. Journal Of Psychiatric Practice 2021, 27: 239-240. PMID: 33939380, DOI: 10.1097/pra.0000000000000553.Commentaries, Editorials and LettersConceptsDiagnostic challengeConstellation of symptomsProminent mood symptomsPosttraumatic stress disorderFemale patientsTrauma-related symptomsMedication treatmentAntipsychotic medicationAdolescent patientsUnnecessary treatmentVisual hallucinationsDifferential diagnosisPatient reportsTerms of stigmaMood symptomsDepressive symptomsPsychotic symptomsSide effectsPatientsPsychotic disordersSuicidal ideasFull differential diagnosisAuditory hallucinationsCotard's syndromeIncorrect diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply